PayPal accounted for $2.26 billion of eBay’s second quarter revenue, more than the $2.12 billion contributed by the core marketplace business. The payments firm processed $66 billion in payments in the second quarter, up 28% on a foreign exchange-neutral basis. It now has 169 million active accounts, up 11% from the same three-month period last year.
From last quarterly report when still consolidated.
Myriad to Present Seven Studies at the ASHG Annual Meeting (October 05, 2015)
SALT LAKE CITY, Oct. 5, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that there will be seven poster presentations featured at American Society for Human Genetics (ASHG) meeting being held Oct. 6 to 10, 2015 in Baltimore, Md.
"At Myriad, we are passionately committed to providing the most accurate hereditary cancer tests through extensively validated laboratory and variant interpretation processes. We have spent almost two decades of research to provide the most sophisticated and comprehensive variant classification program," said Rick Wenstrup, M.D., chief medical officer, Myriad Genetics. "We look forward to presenting these seven new studies at ASHG as we continue to advance the state-of-the-art in variant classification with innovative new approaches."
A study recently published in Gastroenterology describes a variety of germline genetic variants that were identified in a population of 1260 individuals who were referred for clinical genetic testing for Lynch syndrome. Patients were tested at Myriad using a 25 gene hereditary cancer panel. The multigene panel testing identified 114 patients with Lynch syndrome mutations, representing 9% of the patients tested. Furthermore, 71 patients were identified as having a mutation in a gene not associated with Lynch syndrome, representing 5.6% of tested population. Of these patients, fifteen had a mutation in BRCA1 or BRCA2, and an additional 9 patients carried mutations in other genes linked to a high lifetime risk for cancer, including APC, MUTYH, and STK11. The authors concluded that in individuals with suspected Lynch syndrome, multigene panel testing identified high penetrance mutations in cancer predisposition genes, many of which were unexpected based on patients’ histories.
Endometrial cancer is the most common gynecologic malignancy.
NCCN Guidelines for clinical testing recommend genetic testing for all patients diagnosed with endometrial cancer under the age of 50.
According to the National Cancer Institute’s SEER Program, approximately 24% of patients are diagnosed with endometrial cancer before the age of 50.
Ovarian cancer is the most deadly gynecologic cancer. This year in the United States, more than 21,000 new cases of ovarian cancer will be diagnosed, and approximately 14,000 women will die of the disease. The National Comprehensive Cancer Network (NCCN) recommends testing ALL women with ovarian cancer for hereditary cancer, regardless of their age at diagnosis or family history. In fact, NCCN recently updated their guidelines for clinical testing to include the recommendation that all patients with invasive ovarian cancer, not just epithelial, undergo genetic testing. This is due to the association of other ovarian cancer subtypes with hereditary cancer syndromes. For example, sex cord stromal tumors can be seen in patients with Peutz-Jeghers syndrome due to mutations in the STK11 gene. These patients also have high risks of developing other cancers such as breast cancer and pancreatic cancer.
Present Value Calculation Based on 5-Year Forecast – Supports Continued Repurchases
MAXIMIZING LT SHAREHOLDER VALUE
$60 per share present value is what they show on graph!!
• 6% hereditary cancer revenue CAGR since advent of competition • ≈80% of incoming samples ordered as myRisk™ Hereditary Cancer • Long-term pricing arrangements ≈ 45% of revenue • Expanded guidelines for colon & endometrial cancer (+75,000 patients per year) • Breast and pancreatic expansion studies underway and will be completed in FY16 (+90,000 patients per year) • Launched 7 new products (5 internal and 2 acquired) • Published and presented ≈ 250 studies • First FDA approved laboratory developed test (BRACAnalysis CDx™) • Obtained Medicare reimbursement for Prolaris® • Completed 37 companion diagnostic deals • Grew international revenue by over 300%; exiting FY15 at ≈ 4% of revenue • Launched first kit-based product (EndoPredict®) • Direct presence in 11 countries and distribution in ≈50 countries
Profitable R&D driven molecular diagnostic company • Expertise in DNA, RNA and proteins • Strong research capabilities: extensive collaborations ( 50 institutions and 20 pharma/bio companies) • Broad regulatory experience (CLIA, FDA, CE mark) • Deep physician relationships ( 90,000 ordering physicians since inception) • Extensive managed care contracts ( 600) • Reputation for best-in-class quality for highcomplexity tests ( 2 million performed)
Sep 15, 2015
Myriad Outlines Five-Year Strategy to Grow Product Pipeline, Expand InternationallyPremium
ARTICLE: IN-DEPTH—in Molecular Diagnostics
If it is able to implement its strategic goals, Myriad projected, it could have $1.5 billion in annual revenues by fiscal year 2020.
Myriad is committed to helping appropriate patients gain access to genetic risk assessment and testing. As a part of this commitment, we are proud to provide medical professionals with opportunities for ongoing education to learn about advances in genetic risk evaluation and hereditary cancer testing.
We’re pleased to announce the launch of "Gene Panels: The Next Step in Hereditary Cancer Evaluation", a CME course developed by the Postgraduate Institute for Medicine and Miller Medical Communications, with funding provided by an independent educational grant from Myriad Genetics.
Course located at Medscape.